Case Report: Heparin-induced thrombocytopenia in a patient with COVID-19

F1000Res. 2020 Jul 14:9:704. doi: 10.12688/f1000research.24974.2. eCollection 2020.

Abstract

With the spread of the novel coronavirus disease of 2019 (COVID-19) worldwide and associated high incidence of thromboembolic complications, the use of heparin is on the rise. It therefore is crucial to identify patients with contraindications for heparin. Heparin-induced thrombocytopenia (HIT) is a life-threatening complication of exposure to heparin. We report a 66-year-old woman, who was admitted to the hospital with COVID-19 infection. Her course was complicated by pulmonary embolism and dialysis catheter thrombosis. Our patient had a known history of HIT. Treatment of this patient with heparin would have been catastrophic. The COVID-19 pandemic has overwhelmed healthcare systems and is causing a global health crisis. Nevertheless, this case serves as a reminder of the importance of making every effort to obtain thorough history and review of records of every patient.

Keywords: COVID- 19; Heparin-induced thrombocytopenia.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anticoagulants / adverse effects
  • COVID-19*
  • Female
  • Humans
  • Pandemics
  • SARS-CoV-2
  • Thrombocytopenia* / chemically induced

Substances

  • Anticoagulants

Grants and funding

The author(s) declared that no grants were involved in supporting this work.